Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
A jury in the U.S. District Court for the Northern District of California awarded Nektar Therapeutics $90 million in damages plus interest in its lawsuit against Eli Lilly. The jury found that Lilly breached the implied covenant of good faith and fair dealing regarding the license agreement for rezpegaldesleukin. The verdict remains subject to post-trial proceedings and potential appeals.
Sarepta Therapeutics entered into a settlement agreement with REGENXBIO, the University of Pennsylvania, and Catalent to resolve pending patent infringement litigation regarding the '274 and '617 patents. Sarepta will pay a lump sum of $39.0 million to REGENXBIO in exchange for a release of claims and a covenant not to sue regarding Sarepta's gene therapy products using the AAVrh74-based capsid, including ELEVIDYS. The settlement resolves all pending litigations with prejudice and includes no admission of liability.
REGENXBIO and UPenn entered into a settlement agreement with Sarepta Therapeutics and Catalent to resolve all patent infringement litigation regarding U.S. Patent Nos. 10,526,617 and 11,680,274. Sarepta will pay REGENXBIO $39.0 million and receive a covenant not to sue for future claims relating to gene therapy products using an AAVrh74-based capsid, including ELEVIDYS.
Northwest Natural Holding's Texas subsidiaries reached a settlement with the Railroad Commission of Texas staff and municipal parties regarding a general rate case. The stipulation provides for an $8.6 million annual revenue requirement increase and establishes a consolidated rate base of approximately $343 million. The agreement, which is subject to final RRC approval, is expected to result in new rates taking effect in November 2026.
The United States District Court for the Middle District of Florida issued a post-trial ruling in a trademark infringement case against Beyond Meat regarding its 'Great Taste Plant-Based' tagline. The Court significantly reduced a previous jury award of $23.5 million in actual damages to $37,500, while maintaining a $15.4 million disgorgement of profits, resulting in a total judgment of approximately $15.44 million. The company noted that further appeals or motions may be pursued by either party.
Compass Therapeutics received regulatory feedback from the FDA recommending a new clinical trial to demonstrate survival benefit before submitting a Biologics License Application (BLA) for tovecimig in biliary tract cancer. The company disagrees with the recommendation, citing statistically significant improvements in objective response rate and progression-free survival from its Phase 2/3 COMPANION-002 study. Compass intends to further engage with the FDA to determine the path forward for its planned BLA submission.
Stewards, Inc. entered into a confidential settlement agreement with John E. Swenson Co., Inc. to resolve litigation and terminate a $20 million agreement to acquire 'The Hawthorne' property. Under the settlement, the parties will dismiss the pending lawsuit with prejudice, and a $1 million earnest-money deposit will be split, with $900,000 returned to Stewards and $100,000 paid to Swenson.
Credit Acceptance Corporation entered into consent judgments with 40 state attorneys general and the District of Columbia to resolve a 2023 lawsuit and a multi-state investigation into its lending practices. The company will pay $15.5 million to the states, $60 million to a consumer remediation trust, and provide an estimated $634 million in debt relief via balance waivers. The settlement also mandates enhanced consumer disclosures and dealer oversight for a period of five to seven years.
Counterparty
Attorneys General of 40 States and the District of Columbia
Mercury Systems received preliminary court approval for the settlement of two consolidated stockholder derivative actions, Jones v. Aslett and McKinnon v. Aslett. The settlement resolves litigation originally agreed upon in July 2026, with the court issuing formal orders granting preliminary approval on September 9 and September 15, 2026.
Counterparty
Essex County Superior Court for the Commonwealth of Massachusetts
First Northwest Bancorp's subsidiary, First Fed Bank, entered into a settlement agreement with Socotra REIT I, LLC to resolve a 2025 lawsuit alleging misrepresentation and fraud related to a commercial loan transaction. The Bank agreed to pay $1.3 million in exchange for a full release of claims and dismissal of the complaint with prejudice, avoiding further litigation costs and uncertainties.
DataMeds AI entered into a settlement agreement with Brian Norton and other settling parties to resolve litigation in Florida and Delaware concerning a 2023 Membership Interest Purchase Agreement. The company paid $450,000 to settle all claims and repurchase 364,099 shares of common stock, a move expected to extinguish approximately $19 million in liabilities from its balance sheet.
TransparentBusiness, Inc. filed a lawsuit against Universal Navigation Inc. (dba Uniswap Labs) in the U.S. District Court for the Southern District of New York. The company is seeking a declaratory judgment under the Lanham Act to protect its use of the 'Unicoin' trademark. TransparentBusiness stated it intends to pursue the litigation vigorously to secure its intellectual property rights.
Cardiff Oncology entered into a confidential settlement agreement with Nerviano Medical Sciences to resolve litigation in the U.S. District Court for the Southern District of California regarding patent inventorship and license performance. As part of the settlement, the parties amended their 2017 license agreement for onvansertib, updating the royalty structure, exclusivity framework, and granting Nerviano a board observer seat. No monetary payments were made by either party to settle the litigation, which will be dismissed with prejudice.
The U.S. District Court for the Southern District of California has granted preliminary approval for a settlement of a stockholder derivative action against Acadia Pharmaceuticals and certain of its officers and directors. The settlement resolves claims related to the company's drug pimavanserin (NUPLAZID) and includes the implementation of corporate governance reforms and the payment of plaintiff attorney fees. A final settlement hearing is scheduled for January 13, 2027.